Guardant Health price target lowered to $35 from $38 at BofA

BofA lowered the firm’s price target on Guardant Health to $35 from $38 and keeps a Buy rating on the shares. Following Q4 results and guidance, the firm updates forecasts, raising FY24 sales but trimming outyear estimates largely for more conservative minimal residual disease, or MRD, test volume assumptions, the analyst tells investors.